Combination of Anti-miRNAs Oligonucleotides with Low Amounts of Chemotherapeutic Agents for Pancreatic Cancer Therapy
- 1.6k Downloads
Pancreatic ductal adenocarcinoma (PDAC) is the most predominant type of pancreatic cancer and presents one of the highest mortality rates when compared with other carcinomas. The absence of efficient treatment options for PDAC prompted us to investigate whether microRNA inhibition, combined or not with chemotherapeutic agents, would constitute a promising therapeutic approach for this disease. In this chapter, we describe several methods and procedures that can be used to evaluate the potential of new therapeutic strategies involving oligonucleotides against overexpressed microRNAs, in PDAC, either alone or in combination with low amounts of chemotherapeutic drugs.
Key wordsCationic liposomes Lipoplexes Anti-miRNAs oligonucleotides Chemotherapy Combined antitumor strategies Pancreatic cancer therapy
- 1.Saif MW (2011) Pancreatic neoplasm in 2011 : an update. J Pancreas 12:316–321Google Scholar
- 11.Faneca H, Düzgünes N, Pedroso de Lima MC (2010) Fluorescence methods for evaluating lipoplex-mediated gene delivery. In: Weissig V (ed) Methods in molecular biology: liposomes, vol 606. Humana Press Inc., New Jersey, pp 425–437Google Scholar
- 13.Fiske CH, Subbarow Y (1925) The colorimetric determination of phosphorus. J Biol Chem 66:375–400Google Scholar